Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Secondary Adjuvant Long Term Study With Arimidex
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3484
- Registration Number
- NCT00295620
- Locations
- 🇦🇹
Research Site, Zams, Austria
ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.
- Conditions
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3858
- Registration Number
- NCT00291759
- Locations
- 🇦🇹
Research Site, Zams, Austria
🇦🇹Research Sites, Vienna, Austria
🇦🇹Research SIte, Melk, Austria
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2009-06-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1059
- Registration Number
- NCT00287534
- Locations
- 🇩🇪
Research Site, Wuerzburg, Germany
ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2009-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 448
- Registration Number
- NCT00286117
- Locations
- 🇮🇹
Research Site, Vicenza, Italy
A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 205
- Registration Number
- NCT00274469
- Locations
- 🇬🇧
Research Site, Edinburgh, United Kingdom
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 622
- Registration Number
- NCT00265759
- Locations
- 🇺🇸
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States
🇺🇸Doctor's Hospital of Laredo, Laredo, Texas, United States
🇺🇸M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 514
- Registration Number
- NCT00256698
- Locations
- 🇹🇷
Research Site, Istanbul, Turkey
Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Rita Sanghvi, Mehta
- Target Recruit Count
- 42
- Registration Number
- NCT00256217
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 750
- Registration Number
- NCT00253422
- Locations
- 🇬🇧
Royal Marsden - London, London, England, United Kingdom
🇬🇧Institute of Cancer Research - Sutton, Sutton, England, United Kingdom
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
- First Posted Date
- 2005-11-03
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4172
- Registration Number
- NCT00248170
- Locations
- 🇺🇸
Chattanooga Oncology and Hematology Assoicates, PC, Chattanooga, Tennessee, United States
🇺🇸Texas Cancer Center ( Medical City Dallas Hospital), Dallas, Texas, United States
🇺🇸El Paso Cancer Treatment Ctr-East, El Paso, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.